Analysts expect PRA Health Sciences Inc (NASDAQ:PRAH) to post earnings of $1.18 per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for PRA Health Sciences’ earnings, with estimates ranging from $1.14 to $1.23. PRA Health Sciences posted earnings per share of $1.00 during the same quarter last year, which indicates a positive year over year growth rate of 18%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, August 7th.

According to Zacks, analysts expect that PRA Health Sciences will report full-year earnings of $5.04 per share for the current fiscal year, with EPS estimates ranging from $4.99 to $5.10. For the next fiscal year, analysts forecast that the business will post earnings of $5.74 per share, with EPS estimates ranging from $5.67 to $5.87. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that cover PRA Health Sciences.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Wednesday, February 27th. The medical research company reported $1.21 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.03. PRA Health Sciences had a net margin of 5.50% and a return on equity of 26.87%. The firm had revenue of $729.65 million for the quarter, compared to analyst estimates of $750.67 million.

A number of equities research analysts have commented on the company. Robert W. Baird raised their target price on PRA Health Sciences from $119.00 to $122.00 and gave the company an “outperform” rating in a report on Thursday, February 28th. BidaskClub raised PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 14th. Wolfe Research assumed coverage on PRA Health Sciences in a report on Tuesday, April 2nd. They issued a “market perform” rating for the company. SunTrust Banks raised their target price on PRA Health Sciences to $120.00 and gave the company an “average” rating in a report on Monday, March 4th. Finally, ValuEngine raised PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Monday, February 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $113.22.

PRA Health Sciences stock opened at $88.37 on Thursday. PRA Health Sciences has a one year low of $79.20 and a one year high of $121.98. The company has a debt-to-equity ratio of 0.97, a current ratio of 0.90 and a quick ratio of 0.90. The firm has a market capitalization of $5.86 billion, a price-to-earnings ratio of 22.49, a price-to-earnings-growth ratio of 1.20 and a beta of 1.01.

A number of institutional investors have recently added to or reduced their stakes in PRAH. Pendal Group Ltd acquired a new stake in PRA Health Sciences in the fourth quarter valued at $70,530,000. Standard Life Aberdeen plc raised its stake in shares of PRA Health Sciences by 508.0% during the 4th quarter. Standard Life Aberdeen plc now owns 807,592 shares of the medical research company’s stock worth $72,365,000 after buying an additional 674,758 shares during the last quarter. Vanguard Group Inc raised its stake in shares of PRA Health Sciences by 12.8% during the 3rd quarter. Vanguard Group Inc now owns 5,811,972 shares of the medical research company’s stock worth $640,421,000 after buying an additional 658,191 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of PRA Health Sciences by 48.7% during the 1st quarter. AQR Capital Management LLC now owns 1,825,143 shares of the medical research company’s stock worth $199,032,000 after buying an additional 597,699 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of PRA Health Sciences during the 4th quarter worth $53,228,000. 98.14% of the stock is owned by institutional investors.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Further Reading: What is the NASDAQ?

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.